median time on treatment
Objectives: The aims of this retrospective study were to evaluate the median time on treatment (mTOT), overall response rate (ORR), disease control rate (DCR), depth of response, and document the adverse effects of Osimertinib as a first-line treatment in patients with Stage III and IV non-small cell lung cancer and positive EGFR mutation in Ho Chi Minh City Oncology Hospital.
Objectives : The aims of this retrospective study were to evaluate the median time on treatment ( mTOT ), overall response rate ( ORR ), disease control rate ( DCR ), depth of response, and document the adverse effects of Osimertinib as a first-line treatment in patients with Stage III and IV non-small cell lung cancer and positive EGFR mutation in Ho Chi Minh City Oncology Hospital .